In a report released today, Matt Larew from William Blair maintained a Hold rating on Amedisys (AMED – Research Report). The company’s shares ...

UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s ...

Amedisys (Nasdaq: AMED) exceeded Wall Street expectations in its first-quarter results for 2025. The company’s home health segment benefited from ...

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as ...

Reports Q1 revenue $594.8M, consensus $596.49M.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score ...

Amedisys shares have climbed 3% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $93.56, an increase of almost 3% in the last 12 months.

BATON ROUGE, La. (AP) — BATON ROUGE, La. (AP) — Amedisys Inc. (AMED) on Wednesday reported first-quarter earnings of $61 million. On a per-share basis, the Baton Rouge, Louisiana-based company ...